BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile o
Case Number: 6922 Collection: Drugs and Devices, 1940-1963 Evidence Numbers: F. D. C. No. 45462. S. Nos. 36-871 R, 37-079 R, 38-041/3 R, 38-054/5 R. Date Issued: February 1963 Seizure Dates: 11-30-60
Case Number: 6636 Collection: Foods and Drugs, 1908-1943 Evidence Numbers: F. & D. No. 8880. I. S. Nos. 1118-p, 1120-p. Date Issued: March 22, 1920 Seizure Dates: September 25, 1917 Product Keywords: